Claudia Monsalve-Arango
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Claudia Monsalve-Arango has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Andrés Felipe García Ramos
Universidad Pontificia Bolivariana, Medellín, Colombia
3 shared publications - Juanita González Arango
Universidad Pontificia Bolivariana, Medellín, Colombia
3 shared publications - Valentina Estupiñan Vargas
Universidad Pontificia Bolivariana, Medellín, Colombia
3 shared publications - Jaime Alejandro Hincapié-García
Universidad de Antioquía
2 shared publications - José Luis Torres-Grajales
Clínica Las Américas AUNA, Medellín, Colombia
2 shared publications - Natalia Aristizábal Henao
Department of Endocrinology, Universidad Pontificia Bolivariana, Medellín, Colombia
2 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 13 (3)
Clinical management of homozygous familial hypercholesterolemia: Perspectives from an expert panel
Introduction: Homozygous familial hypercholesterolemia (HoFH) is a rare but severe genetic disorder characterized by extremely elevated LDL-C levels from birth, leading to accelerated atherosclerosis and premature cardiovascular disease. Despite advances in lipid-lowering therapies, the evidence guiding clinical practice remains heterogeneous, highlighting the need for an expert consensus to synthesize available data and provide practical recommendations. Objective: This narrative review aims to unify current medical evidence to guide the management of homozygous familial hypercholesterolemia (HoFH). Through a multidisciplinary expert consensus, the panel seeks to synthesize the available scientific information on HoFH. The main objective is to provide the medical community with practical, clear recommendations to optimize patient care, emphasizing three fundamental areas: improving the accuracy of early diagnosis, structuring comprehensive clinical management, and evaluating the effectiveness of emerging therapies. Ultimately, the panel's goal is to support actions to reduce the risk of premature cardiovascular disease, as well as to standardize the care of HoFH. Methodology: This narrative review was developed through a multidisciplinary consensus process. Experts in internal medicine, cardiology, endocrinology, paediatrics, and medical genetics defined key topics, drafted sections according to their expertise, and iteratively refined the content through collaborative discussions. Evidence was selected pragmatically, based on clinical relevance and applicability, to inform diagnosis, management, and emerging therapies for HoFH. Results: The review addresses major domains in the care of HoFH, including clinical and genetic diagnosis, differential diagnosis, cascade screening, cardiovascular risk assessment, and therapeutic approaches. Both non-pharmacological and pharmacological interventions are discussed, from statins and ezetimibe to lomitapide, evinacumab, and novel emerging therapies. Special populations such as paediatric patients and pregnant women are also considered. Additionally, the review highlights the social and public health impact of HoFH, emphasizing the importance of early detection and equitable access to advanced therapies. Conclusions: HoFH is more prevalent than previously recognised and requires early diagnosis and comprehensive management. This consensus synthesizes expert experience and current evidence to provide practical guidance for clinicians. By integrating pharmacological, non-pharmacological, and genetic strategies, it aims to improve outcomes and reduce the cardiovascular burden of HoFH.
- 10 August 2026
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 13 (3)
Open AccessClinical management of homozygous familial hypercholesterolemia: Perspectives from an expert panel
Introduction: Homozygous familial hypercholesterolemia (HoFH) is a rare but severe genetic disorder characterized by extremely elevated LDL-C levels from birth, leading to accelerated atherosclerosis and premature cardiovascular disease. Despite advances in lipid-lowering therapies, the evidence guiding clinical practice remains heterogeneous, highlighting the need for an expert consensus to synthesize available data and provide practical recommendations. Objective: This narrative review aims to unify current medical evidence to guide the management of homozygous familial hypercholesterolemia (HoFH). Through a multidisciplinary expert consensus, the panel seeks to synthesize the available scientific information on HoFH. The main objective is to provide the medical community with practical, clear recommendations to optimize patient care, emphasizing three fundamental areas: improving the accuracy of early diagnosis, structuring comprehensive clinical management, and evaluating the effectiveness of emerging therapies. Ultimately, the panel's goal is to support actions to reduce the risk of premature cardiovascular disease, as well as to standardize the care of HoFH. Methodology: This narrative review was developed through a multidisciplinary consensus process. Experts in internal medicine, cardiology, endocrinology, paediatrics, and medical genetics defined key topics, drafted sections according to their expertise, and iteratively refined the content through collaborative discussions. Evidence was selected pragmatically, based on clinical relevance and applicability, to inform diagnosis, management, and emerging therapies for HoFH. Results: The review addresses major domains in the care of HoFH, including clinical and genetic diagnosis, differential diagnosis, cascade screening, cardiovascular risk assessment, and therapeutic approaches. Both non-pharmacological and pharmacological interventions are discussed, from statins and ezetimibe to lomitapide, evinacumab, and novel emerging therapies. Special populations such as paediatric patients and pregnant women are also considered. Additionally, the review highlights the social and public health impact of HoFH, emphasizing the importance of early detection and equitable access to advanced therapies. Conclusions: HoFH is more prevalent than previously recognised and requires early diagnosis and comprehensive management. This consensus synthesizes expert experience and current evidence to provide practical guidance for clinicians. By integrating pharmacological, non-pharmacological, and genetic strategies, it aims to improve outcomes and reduce the cardiovascular burden of HoFH.
- Open Access
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (5) , 1-6
Clinical and functional evidence supporting pathogenicity of a novel APOA5 variant in familial chylomicronemia syndrome
Objective: This study aimed to evaluate the clinical and functional impact of a novel apolipoprotein A5 (ApoA5) variant by assessing lipoprotein lipase (LPL) activity. Subjects and methods: Demographic and clinical data, including blood lipid levels and body mass index, were retrospectively collected from an endocrinology clinic registry. Ten individuals with familial chylomicronemia syndrome (FCS) carrying a novel APOA5 variant were included. Whole-exome sequencing was performed using the latest generation DNB-SEQ400 platform. LPL activity was measured in post-heparin plasma using a radiometric assay. Statistical analysis: Categorical variables were summarized as frequencies and percentages, and continuous variables as mean ± standard deviation or median (range), as appropriate. Group comparisons were performed using the Mann-Whitney U test or chi-square test. Analyses were conducted using the Statistical Package for the Social Sciences software (v. 25.0). A p-value < 0.05 was considered statistically significant. Results: We report ten cases of FCS with a homozygous missense variant of uncertain significance in APOA5: c.694T>C; p.(Ser232Pro), located in exon 3. In six patients assessed for LPL activity, levels remained consistently below 20% compared to normotriglyceridemic controls. The addition of exogenous serum containing APOA5 restored LPL activity to above 20% in all cases, indicating functional rescue. Conclusion: Measurement of LPL activity demonstrated the functional impact of the APOA5 c.694T>C; p.(Ser232Pro) variant. These findings support reclassification of the variant as likely pathogenic and enable differentiation from multifactorial chylomicronemia syndrome.
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (5) , 1-6
Open AccessClinical and functional evidence supporting pathogenicity of a novel APOA5 variant in familial chylomicronemia syndrome
Objective: This study aimed to evaluate the clinical and functional impact of a novel apolipoprotein A5 (ApoA5) variant by assessing lipoprotein lipase (LPL) activity. Subjects and methods: Demographic and clinical data, including blood lipid levels and body mass index, were retrospectively collected from an endocrinology clinic registry. Ten individuals with familial chylomicronemia syndrome (FCS) carrying a novel APOA5 variant were included. Whole-exome sequencing was performed using the latest generation DNB-SEQ400 platform. LPL activity was measured in post-heparin plasma using a radiometric assay. Statistical analysis: Categorical variables were summarized as frequencies and percentages, and continuous variables as mean ± standard deviation or median (range), as appropriate. Group comparisons were performed using the Mann-Whitney U test or chi-square test. Analyses were conducted using the Statistical Package for the Social Sciences software (v. 25.0). A p-value < 0.05 was considered statistically significant. Results: We report ten cases of FCS with a homozygous missense variant of uncertain significance in APOA5: c.694T>C; p.(Ser232Pro), located in exon 3. In six patients assessed for LPL activity, levels remained consistently below 20% compared to normotriglyceridemic controls. The addition of exogenous serum containing APOA5 restored LPL activity to above 20% in all cases, indicating functional rescue. Conclusion: Measurement of LPL activity demonstrated the functional impact of the APOA5 c.694T>C; p.(Ser232Pro) variant. These findings support reclassification of the variant as likely pathogenic and enable differentiation from multifactorial chylomicronemia syndrome.
- Open Access
- 13 December 2024
- Published by Universidad Nacional de Córdoba in Revista de la Facultad de Ciencias Médicas de Córdoba
- Vol. 81 (4) , 824-841
Desvelando Secretos Hormonales
Background: Thyroid dysfunction during pregnancy negatively impacts both the woman and her offspring, with the early gestational period being critical for potential repercussions. Establishing pre-conception and during-conception care strategies is crucial for favorable pregnancy outcomes. Objective: This review aims to compile the most recent scientific evidence to guide diagnostic and therapeutic approaches based on clinical cases, including a description of thyroid physiology during pregnancy and strategies for identifying high-risk patients for treatment. Method: This bibliographic review combined DeCS and MeSH terms from the PICOT question, spanning the period from 2015 to 2022 across 5 databases. Articles in both English and Spanish were included if they addressed the PICOT question and contributed to the explanation of two case reports. Results: A total of 1452 articles were collected, which, following an initial elimination of duplicates and subsequent blind review based on inclusion and exclusion criteria by two reviewers, resulted in 32 articles included in this review. Conclusions: Overt hypothyroidism is associated with adverse maternal-fetal outcomes, and its treatment improves these complications. However, in borderline conditions such as subclinical hypothyroidism, isolated hypothyroxinemia, and thyroid autoimmune conditions, uncertainty about the treatment's impact persists due to a scarcity of controlled trials. Emphasizing the importance of all physicians being familiar with this condition during gestation.
- 13 December 2024
- Published by Universidad Nacional de Córdoba in Revista de la Facultad de Ciencias Médicas de Córdoba
- Vol. 81 (4) , 824-841
Open AccessDesvelando Secretos Hormonales
Background: Thyroid dysfunction during pregnancy negatively impacts both the woman and her offspring, with the early gestational period being critical for potential repercussions. Establishing pre-conception and during-conception care strategies is crucial for favorable pregnancy outcomes. Objective: This review aims to compile the most recent scientific evidence to guide diagnostic and therapeutic approaches based on clinical cases, including a description of thyroid physiology during pregnancy and strategies for identifying high-risk patients for treatment. Method: This bibliographic review combined DeCS and MeSH terms from the PICOT question, spanning the period from 2015 to 2022 across 5 databases. Articles in both English and Spanish were included if they addressed the PICOT question and contributed to the explanation of two case reports. Results: A total of 1452 articles were collected, which, following an initial elimination of duplicates and subsequent blind review based on inclusion and exclusion criteria by two reviewers, resulted in 32 articles included in this review. Conclusions: Overt hypothyroidism is associated with adverse maternal-fetal outcomes, and its treatment improves these complications. However, in borderline conditions such as subclinical hypothyroidism, isolated hypothyroxinemia, and thyroid autoimmune conditions, uncertainty about the treatment's impact persists due to a scarcity of controlled trials. Emphasizing the importance of all physicians being familiar with this condition during gestation.
- Open Access
- 10 April 2023
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 10 (2)
Hiperaldosteronismo causado por quiste adrenal
Introducción: los quistes adrenales son poco comunes, en especial los de tipo funcional, ya que solo se hallaron 3 casos reportados en la literatura. Objetivo: presentar un caso clínico de un paciente con hiperaldosteronismo asociado a un quiste adrenal. Presentación del caso: paciente masculino de 39 años con hipertensión arterial desde los 38 años al cual se le deciden realizar estudios de hipertensión secundaria, encontrando como hallazgo positivo hiperaldosteronismo primario en la evaluación inicial. Se realizó confirmación bioquímica con test de supresión con solución con un posterior hallazgo de adenoma adrenal izquierdo de baja densidad en TAC de abdomen contrastado, por lo que fue llevado a que se le realizara una adrenalectomía laparoscópica con curación bioquímica, según evaluación a los cuatro meses postoperatorios sin uso de antihipertensivos. Discusión y conclusión: los quistes adrenales generalmente se presentan unilateralmente con diferentes categorías histopatológicas, además, lo usual es que sean no funcionales. El hiperaldosteronismo primario es una causa común de hipertensión secundaria y puede estar asociado a complicaciones cardiovasculares. Su diagnóstico se basa en la medición de aldosterona y renina en sangre y confirmación bioquímica, con posterior evaluación de localización, incluyendo, en la mayoría de los casos, cateterismo de venas suprarrenales para determinar la causa subyacente. Nuestro paciente constituye el cuarto caso publicado en la literatura sobre un quiste con sobreproducción hormonal confirmado bioquímicamente, lo cual es importante para no descartar la presencia de quistes como posible etiología de producción hormonal que, si bien no es lo más común, es posible encontrarlos.
- 10 April 2023
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 10 (2)
Open AccessHiperaldosteronismo causado por quiste adrenal
Introducción: los quistes adrenales son poco comunes, en especial los de tipo funcional, ya que solo se hallaron 3 casos reportados en la literatura. Objetivo: presentar un caso clínico de un paciente con hiperaldosteronismo asociado a un quiste adrenal. Presentación del caso: paciente masculino de 39 años con hipertensión arterial desde los 38 años al cual se le deciden realizar estudios de hipertensión secundaria, encontrando como hallazgo positivo hiperaldosteronismo primario en la evaluación inicial. Se realizó confirmación bioquímica con test de supresión con solución con un posterior hallazgo de adenoma adrenal izquierdo de baja densidad en TAC de abdomen contrastado, por lo que fue llevado a que se le realizara una adrenalectomía laparoscópica con curación bioquímica, según evaluación a los cuatro meses postoperatorios sin uso de antihipertensivos. Discusión y conclusión: los quistes adrenales generalmente se presentan unilateralmente con diferentes categorías histopatológicas, además, lo usual es que sean no funcionales. El hiperaldosteronismo primario es una causa común de hipertensión secundaria y puede estar asociado a complicaciones cardiovasculares. Su diagnóstico se basa en la medición de aldosterona y renina en sangre y confirmación bioquímica, con posterior evaluación de localización, incluyendo, en la mayoría de los casos, cateterismo de venas suprarrenales para determinar la causa subyacente. Nuestro paciente constituye el cuarto caso publicado en la literatura sobre un quiste con sobreproducción hormonal confirmado bioquímicamente, lo cual es importante para no descartar la presencia de quistes como posible etiología de producción hormonal que, si bien no es lo más común, es posible encontrarlos.
- Open Access
- 12 October 2022
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 9 (4)
Hipofisitis con imagen normal
Background: A hypophysitis is an inflammatory disease of the pituitary gland that compromise any portion of the gland and compromise the hormonal axes. Among the primary causes, the most frequent is lymphocytic or autoimmune hypophysitis. Purpose: To present an interesting case and it’s clinical approach. Case presentation: In the text we present a patient with history of lupus in whom pituitary hormone deficiencies were documented with a presumptive diagnosis of autoimmune hypophysitis. The diagnosis was based on clinical and laboratory findings. Cranial images were unremarkable, ruling out differential diagnoses Discussion and conclusion: Hypophysitis can be classified as primary or secondary depending on the underlining cause. The final diagnosis is made with the pathology report. Cranial images support the diagnosis and help to rule out differentials but there have been described cases of hypophitis with normal images. We present the diagnostic approach to pituitary hormone deficiency in a patient with autoimmune disease with suspected adenohypophysitis based on clinical symptoms, history and biochemical profile, even in the context of normal images. Introducción: la hipofisitis es una enfermedad inflamatoria de la hipófisis que puede comprometer cualquier porción de la glándula y generar alteración en los ejes hormonales. Dentro de las causas primarias la más frecuente es la hipofisitis linfocítica o autoinmune. Objetivo: presentar un caso de interés con el abordaje clínico realizado. Presentación del caso: en el texto se presenta el caso de una paciente con antecedente personal de lupus a quien se le documentan deficiencias hormonales hipofisiarias y en quien se realiza un diagnóstico presuntivo de hipofisitis autoinmune con base en la clínica y los hallazgos de laboratorios, pero con imágenes craneales normales, descartando los demás diagnósticos diferenciales. Discusión y conclusión: la hipofisitis se puede clasificar como primaria o secundaria según la causa, el diagnóstico definitivo es con la patología que en muchos casos no es necesaria. Las imágenes de silla turca apoyan el diagnóstico y ayudan a descartar diferenciales, pero existen casos descritos de hipofisitis con exámenes normales. Además, se presenta el abordaje diagnóstico a la deficiencia de hormonas pituitarias en una paciente con enfermedad autoinmune con sospecha de adenohipofisitis por clínica, antecedentes y perfil bioquímico aun en el contexto de imágenes normales.
- 12 October 2022
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 9 (4)
Open AccessHipofisitis con imagen normal
Background: A hypophysitis is an inflammatory disease of the pituitary gland that compromise any portion of the gland and compromise the hormonal axes. Among the primary causes, the most frequent is lymphocytic or autoimmune hypophysitis. Purpose: To present an interesting case and it’s clinical approach. Case presentation: In the text we present a patient with history of lupus in whom pituitary hormone deficiencies were documented with a presumptive diagnosis of autoimmune hypophysitis. The diagnosis was based on clinical and laboratory findings. Cranial images were unremarkable, ruling out differential diagnoses Discussion and conclusion: Hypophysitis can be classified as primary or secondary depending on the underlining cause. The final diagnosis is made with the pathology report. Cranial images support the diagnosis and help to rule out differentials but there have been described cases of hypophitis with normal images. We present the diagnostic approach to pituitary hormone deficiency in a patient with autoimmune disease with suspected adenohypophysitis based on clinical symptoms, history and biochemical profile, even in the context of normal images. Introducción: la hipofisitis es una enfermedad inflamatoria de la hipófisis que puede comprometer cualquier porción de la glándula y generar alteración en los ejes hormonales. Dentro de las causas primarias la más frecuente es la hipofisitis linfocítica o autoinmune. Objetivo: presentar un caso de interés con el abordaje clínico realizado. Presentación del caso: en el texto se presenta el caso de una paciente con antecedente personal de lupus a quien se le documentan deficiencias hormonales hipofisiarias y en quien se realiza un diagnóstico presuntivo de hipofisitis autoinmune con base en la clínica y los hallazgos de laboratorios, pero con imágenes craneales normales, descartando los demás diagnósticos diferenciales. Discusión y conclusión: la hipofisitis se puede clasificar como primaria o secundaria según la causa, el diagnóstico definitivo es con la patología que en muchos casos no es necesaria. Las imágenes de silla turca apoyan el diagnóstico y ayudan a descartar diferenciales, pero existen casos descritos de hipofisitis con exámenes normales. Además, se presenta el abordaje diagnóstico a la deficiencia de hormonas pituitarias en una paciente con enfermedad autoinmune con sospecha de adenohipofisitis por clínica, antecedentes y perfil bioquímico aun en el contexto de imágenes normales.
- Open Access
- 18 July 2022
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 9 (3)
Hipofisitis y adrenalitis asociada al uso de inhibidores del punto de control inmunitario
Introducción: los inhibidores de punto de control inmunitario (IPCI) han revolucionado el tratamiento de los pacientes con cáncer, incrementando la supervivencia libre de enfermedad y son terapias con aval para el manejo de neoplasias sólidas. Entre los eventos adversos frecuentes se encuentran los que ocurren a nivel del sistema endocrino y se reporta el caso de una paciente tratada con anti CTLA-4 y anti PD-1 que desarrolló hipofisitis y adrenalitis. Objetivo: describir el caso de una paciente que presentó endocrinopatías (hipofisitis y adrenalitis) asociadas al uso de IPCI, en una clínica en la ciudad de Medellín, Colombia. Presentación del caso: mujer de 74 años con antecedente de carcinoma de células renales tratada con ipilimumab y nivolumab, suspendidos por neumonitis. Tres meses después acudió a urgencias por disminución de clase funcional y somnolencia, el examen físico mostró hipotensión y se evidenció hiponatremia, hipotónica y cortisol basal disminuido. Por ello, se solicitó perfil hipofisario, encontrando somatomedina y hormona folículo estimulante (FSH) bajas y hormona adrenocorticotropa ACTH elevada, además, se realizó resonancia de silla turca sin alteración estructural y se concluyó hipofisitis con imagen normal e insuficiencia adrenal primaria secundaria a adrenalitis. Discusión y conclusión: los inhibidores del punto de control inmunitario son medicamentos actualmente utilizados para diferentes tipos de neoplasias, estos medicamentos se asocian en un porcentaje significativo con endocrinopatías, sin embargo, encontrar la afectación de dos glándulas endocrinas es inusual, este es el segundo caso reportado en la literatura con hipofisitis y adrenalitis. Se deben reconocer las manifestaciones clínicas de las endocrinopatías asociadas a la inmunoterapia, teniendo en cuenta el uso creciente de estas terapias para diferentes neoplasias. El compromiso de más de una glándula endocrina es infrecuente, sin embargo, se debe sospechar y reconocer. Además, es importante establecer en cada centro un protocolo para el abordaje y el seguimiento de estos pacientes.
- 18 July 2022
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 9 (3)
Open AccessHipofisitis y adrenalitis asociada al uso de inhibidores del punto de control inmunitario
Introducción: los inhibidores de punto de control inmunitario (IPCI) han revolucionado el tratamiento de los pacientes con cáncer, incrementando la supervivencia libre de enfermedad y son terapias con aval para el manejo de neoplasias sólidas. Entre los eventos adversos frecuentes se encuentran los que ocurren a nivel del sistema endocrino y se reporta el caso de una paciente tratada con anti CTLA-4 y anti PD-1 que desarrolló hipofisitis y adrenalitis. Objetivo: describir el caso de una paciente que presentó endocrinopatías (hipofisitis y adrenalitis) asociadas al uso de IPCI, en una clínica en la ciudad de Medellín, Colombia. Presentación del caso: mujer de 74 años con antecedente de carcinoma de células renales tratada con ipilimumab y nivolumab, suspendidos por neumonitis. Tres meses después acudió a urgencias por disminución de clase funcional y somnolencia, el examen físico mostró hipotensión y se evidenció hiponatremia, hipotónica y cortisol basal disminuido. Por ello, se solicitó perfil hipofisario, encontrando somatomedina y hormona folículo estimulante (FSH) bajas y hormona adrenocorticotropa ACTH elevada, además, se realizó resonancia de silla turca sin alteración estructural y se concluyó hipofisitis con imagen normal e insuficiencia adrenal primaria secundaria a adrenalitis. Discusión y conclusión: los inhibidores del punto de control inmunitario son medicamentos actualmente utilizados para diferentes tipos de neoplasias, estos medicamentos se asocian en un porcentaje significativo con endocrinopatías, sin embargo, encontrar la afectación de dos glándulas endocrinas es inusual, este es el segundo caso reportado en la literatura con hipofisitis y adrenalitis. Se deben reconocer las manifestaciones clínicas de las endocrinopatías asociadas a la inmunoterapia, teniendo en cuenta el uso creciente de estas terapias para diferentes neoplasias. El compromiso de más de una glándula endocrina es infrecuente, sin embargo, se debe sospechar y reconocer. Además, es importante establecer en cada centro un protocolo para el abordaje y el seguimiento de estos pacientes.
- 1 January 2018
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 31 (6) , 696-700
Maternal and perinatal outcomes in pregnant women with type 1 diabetes treated with continuous subcutaneous insulin infusion and real time continuous glucose monitoring in two specialized centers in Medellin, Colombia
Objective: We assessed maternal and perinatal outcomes in pregnant women with type 1 diabetes, treated with continuous subcutaneous insulin infusion and real time continuous glucose monitoring. Methods: This is a retrospective study, analyzing the basal characteristics, glycemic control, maternal and perinatal outcomes of pregnant women with type 1 diabetes, who were on an insulin pump with continuous glucose monitoring between 2011 and 2015. Results: Fourteen patients were included. The median age was 33 and disease duration 12 years. Indications for therapy were mainly poor glycemic control and severe hypoglycemia. The median A1c decrease was 1.02% between the first and third trimester. Pregnancies were associated with complications: 7.1% of the patients had diabetic ketoacidosis, 7.1% had an abortion, 28.5% gestational hypertension and 12.2% preeclampsia. The median gestational age at birth was 37 weeks and four days; the frequency of preterm birth was 7.1% and macrosomia 21.4%. There were no congenital malformations or perinatal death. Conclusions: Baseline characteristics and results of patients in this study were similar to those reported in the previous literature. Continuous subcutaneous insulin infusion with continuous glucose monitoring is an alternative treatment option for pregnant women with type 1 diabetes before or during pregnancy.
- 1 January 2018
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 31 (6) , 696-700
Maternal and perinatal outcomes in pregnant women with type 1 diabetes treated with continuous subcutaneous insulin infusion and real time continuous glucose monitoring in two specialized centers in Medellin, Colombia
Objective: We assessed maternal and perinatal outcomes in pregnant women with type 1 diabetes, treated with continuous subcutaneous insulin infusion and real time continuous glucose monitoring. Methods: This is a retrospective study, analyzing the basal characteristics, glycemic control, maternal and perinatal outcomes of pregnant women with type 1 diabetes, who were on an insulin pump with continuous glucose monitoring between 2011 and 2015. Results: Fourteen patients were included. The median age was 33 and disease duration 12 years. Indications for therapy were mainly poor glycemic control and severe hypoglycemia. The median A1c decrease was 1.02% between the first and third trimester. Pregnancies were associated with complications: 7.1% of the patients had diabetic ketoacidosis, 7.1% had an abortion, 28.5% gestational hypertension and 12.2% preeclampsia. The median gestational age at birth was 37 weeks and four days; the frequency of preterm birth was 7.1% and macrosomia 21.4%. There were no congenital malformations or perinatal death. Conclusions: Baseline characteristics and results of patients in this study were similar to those reported in the previous literature. Continuous subcutaneous insulin infusion with continuous glucose monitoring is an alternative treatment option for pregnant women with type 1 diabetes before or during pregnancy.
- 1 November 2016
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 18 (11) , 713-718
Clinical Outcomes After 1 Year of Augmented Insulin Pump Therapy in Patients with Diabetes in a Specialized Diabetes Center in Medellín, Colombia
Background: Type 1 diabetes can be difficult to control. Augmented pump therapy (CSII-rtCGM) has become an important tool for controlling blood glucose and decreasing hypoglycemia. Methods: Describe the results 1 year after starting CSII-rtCGM in patients with diabetes in Medellín, Colombia. This is an observational, retrospective study. Patients with type 1 and type 2 diabetes started on CSII-rtCGM between January 2008 and June 2015 were included. Qualitative variables were analyzed as absolute or relative frequencies. Quantitative variables were obtained through central tendency and dispersion according to the normal distribution of the analyzed variable using Kolmogorov–Smirnov. SPSS 19 from IBM was used. Results: Two hundred forty-seven patients were identified, of those 183 were included. The starting HbA1C was 8.7% ± 1.7% and 7.4% ± 0.8% ( P < 0.05) 1 year later. 16.5% of patients had been admitted to the hospital before starting CSII-rtCGM, after 1 year the admission rate was 6.0% ( P < 0.05). The incidence of severe hypoglycemia at the beginning was 32%, 1 year later it was 7.1%. Conclusion: CSII-rtCGM therapy improves glucose control and decreases severe hypoglycemic events and hospital admission rate.
- 1 November 2016
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 18 (11) , 713-718
Clinical Outcomes After 1 Year of Augmented Insulin Pump Therapy in Patients with Diabetes in a Specialized Diabetes Center in Medellín, Colombia
Background: Type 1 diabetes can be difficult to control. Augmented pump therapy (CSII-rtCGM) has become an important tool for controlling blood glucose and decreasing hypoglycemia. Methods: Describe the results 1 year after starting CSII-rtCGM in patients with diabetes in Medellín, Colombia. This is an observational, retrospective study. Patients with type 1 and type 2 diabetes started on CSII-rtCGM between January 2008 and June 2015 were included. Qualitative variables were analyzed as absolute or relative frequencies. Quantitative variables were obtained through central tendency and dispersion according to the normal distribution of the analyzed variable using Kolmogorov–Smirnov. SPSS 19 from IBM was used. Results: Two hundred forty-seven patients were identified, of those 183 were included. The starting HbA1C was 8.7% ± 1.7% and 7.4% ± 0.8% ( P < 0.05) 1 year later. 16.5% of patients had been admitted to the hospital before starting CSII-rtCGM, after 1 year the admission rate was 6.0% ( P < 0.05). The incidence of severe hypoglycemia at the beginning was 32%, 1 year later it was 7.1%. Conclusion: CSII-rtCGM therapy improves glucose control and decreases severe hypoglycemic events and hospital admission rate.